Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 3/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12792475 | 1.00 | THRA (0.44) | THRATHRBDGKADNM1ALDH1A1 | |
| SCHEMBL889272 | 0.90 | THRA (0.34) | THRATHRBDGKADNM1ALDH1A1 | |
| SCHEMBL10820626 | 0.83 | FAAH (0.43) | THRATHRBALDH1A1KMT2ANAAA | |
| SCHEMBL889325 | 0.81 | DGKA (0.42) | DGKAALDH1A1MEN1GAAKMT2A | |
| SCHEMBL2999894 | 0.80 | NAAA (0.47) | DGKAALDH1A1NAAALMNAFAAH | |
| SCHEMBL3005332 | 0.80 | NAAA (0.47) | DGKAALDH1A1NAAALMNAFAAH | |
| SCHEMBL3005045 | 0.80 | NAAA (0.47) | DGKAALDH1A1NAAALMNAFAAH | |
| SCHEMBL12847847 | 0.80 | HPRT1 (0.39) | ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL12792322 | 0.79 | CASP2 (0.44) | DNM1ALDH1A1MEN1KMT2ANAAA | |
| SCHEMBL12791900 | 0.79 | CASP2 (0.44) | DNM1ALDH1A1MEN1KMT2ANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | FCGRT, MYD88, C3AR1 | THRA 3682/4885THRB 4260/4885DGKA 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.